Employerโฃ Concerns Rise Over GLP-1 Drug Costs for โWeight Loss
Published: November 26, 2025
As more large employers begin to includeโ GLP-1 drugsโ in theirโค health benefit plans for โขweight loss, โคaโฃ growing concernโฃ over the substantial cost โof these medications is emerging.Recent discussions with โขemployers reveal thatโฃ many are actively considering adjustments to their coverage policies, potentially scaling back benefits or implementing stricter requirements for access.
A new analysis, โbased on โฃfindings from the 2025 KFF Employer Health Benefits Survey, provides valuable insightsโ into these employer perspectives. โขThe analysis draws upon interviews and group discussionsโ withโค HR directorsโ and benefits managers responsible for overseeing employer-sponsored โhealth plans.
The researchโค encompassed five focus groups held across โthe United States throughout the summer andโ fallโ ofโค 2025, representing over one hundred companies and a combined workforce exceedingโค a quarterโค of a million employees. These โฃconversations highlighted the complex considerations employers face when โขdetermining โขcoverage for these increasingly โฃpopular, yet expensive, medications.
Further โฃdataโ and complete analysisโฃ onโข health costs are readily available onโค the โ Peterson-KFF Health System tracker,โค a leading online resource dedicated โto monitoring and evaluatingโ theโ performance of the U.S. health system.
We hope โคyou found this article informative. The landscape ofโข healthcare benefits is constantly evolving,โฃ and we’re โcommitted to bringingโ you the latest insights.If you โhave thoughts on this topic,โข pleaseโ share themโ in the โcomments below! โDon’t forget to โsubscribe to our newsletter for more in-depth coverage of health policy โคand industry โtrends.
